See more : Dadi International Group Limited (8130.HK) Income Statement Analysis – Financial Results
Complete financial analysis of REGENXBIO Inc. (RGNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of REGENXBIO Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Vikas Lifecare Limited (VIKASLIFE.NS) Income Statement Analysis – Financial Results
- Good Friend International Holdings Inc. (912398.TW) Income Statement Analysis – Financial Results
- Horace Mann Educators Corporation (HMN) Income Statement Analysis – Financial Results
- TPT Global Tech, Inc. (TPTW) Income Statement Analysis – Financial Results
- Venky’s (India) Limited (VENKEYS.NS) Income Statement Analysis – Financial Results
REGENXBIO Inc. (RGNX)
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.24M | 112.72M | 470.35M | 154.57M | 35.23M | 218.51M | 10.39M | 4.59M | 7.59M | 6.12M | 6.09M |
| Cost of Revenue | 37.21M | 54.55M | 51.83M | 35.71M | 8.24M | 9.64M | 1.71M | 959.00K | 1.50M | 1.01M | 324.00K |
| Gross Profit | 53.03M | 58.18M | 418.51M | 118.85M | 26.99M | 208.87M | 8.68M | 3.63M | 6.09M | 5.11M | 5.76M |
| Gross Profit Ratio | 58.76% | 51.61% | 88.98% | 76.89% | 76.61% | 95.59% | 83.56% | 79.10% | 80.19% | 83.55% | 94.68% |
| Research & Development | 232.27M | 242.45M | 181.44M | 166.29M | 124.19M | 83.87M | 57.22M | 45.48M | 17.28M | 4.96M | 5.05M |
| General & Administrative | 88.49M | 85.28M | 79.33M | 63.82M | 51.82M | 36.85M | 27.23M | 23.59M | 11.91M | 3.85M | 5.47M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 88.49M | 85.28M | 79.33M | 63.82M | 51.82M | 36.85M | 27.23M | 23.59M | 11.91M | 3.85M | 5.47M |
| Other Expenses | 397.00K | -6.68M | -2.24M | 7.98M | -10.00K | 42.00K | 116.00K | -102.00K | -26.00K | -47.00K | 0.00 |
| Operating Expenses | 321.16M | 321.06M | 258.53M | 238.09M | 175.99M | 120.77M | 84.57M | 68.97M | 29.17M | 8.77M | 10.53M |
| Cost & Expenses | 358.37M | 375.60M | 310.37M | 273.80M | 184.23M | 130.41M | 86.28M | 69.93M | 30.67M | 9.77M | 10.85M |
| Interest Income | 25.00K | 342.00K | 719.00K | 4.27M | 2.95M | 8.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.86M | 23.25M | 26.28M | 771.00K | 0.00 | 0.00 | 0.00 | 0.00 | 20.00K | 321.00K | 611.00K |
| Depreciation & Amortization | 17.32M | 12.91M | 9.56M | 8.41M | 7.15M | 3.98M | 2.69M | 544.00K | 80.00K | 30.00K | 14.00K |
| EBITDA | -239.46M | -244.24M | 169.54M | -96.83M | -90.34M | 92.08M | -73.20M | -64.80M | -22.71M | -3.65M | -4.78M |
| EBITDA Ratio | -265.36% | -232.90% | 34.17% | -74.38% | -560.72% | 37.08% | -756.29% | -1,423.84% | -304.16% | -59.67% | -78.23% |
| Operating Income | -268.13M | -262.88M | 159.98M | -119.23M | -149.00M | 88.10M | -75.89M | -65.34M | -23.14M | -3.68M | -4.78M |
| Operating Income Ratio | -297.12% | -233.20% | 34.01% | -77.14% | -422.89% | 40.32% | -730.15% | -1,423.84% | -304.92% | -60.16% | -78.46% |
| Total Other Income/Expenses | 4.48M | -17.53M | -18.73M | 13.22M | 51.51M | 16.02M | 2.72M | 1.94M | 326.00K | -321.00K | -611.00K |
| Income Before Tax | -263.65M | -280.41M | 141.25M | -106.01M | -97.49M | 104.12M | -73.17M | -63.40M | -22.81M | -4.00M | -5.39M |
| Income Before Tax Ratio | -292.15% | -248.75% | 30.03% | -68.59% | -276.70% | 47.65% | -704.02% | -1,381.61% | -300.62% | -65.41% | -88.50% |
| Income Tax Expense | -152.00K | -84.00K | 13.41M | 5.24M | -2.76M | 4.18M | 686.00K | -435.00K | -60.00K | 291.00K | 597.00K |
| Net Income | -263.49M | -280.32M | 127.84M | -111.25M | -94.73M | 99.94M | -73.17M | -62.97M | -22.81M | -4.00M | -5.39M |
| Net Income Ratio | -291.99% | -248.68% | 27.18% | -71.98% | -268.88% | 45.74% | -704.02% | -1,372.13% | -300.62% | -65.41% | -88.50% |
| EPS | -6.02 | -6.50 | 3.01 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | -2.49 | -0.30 | -0.41 |
| EPS Diluted | -6.02 | -6.50 | 2.91 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | -2.49 | -0.30 | -0.41 |
| Weighted Avg Shares Out | 43.73M | 43.15M | 42.44M | 37.28M | 36.69M | 36.61M | 29.86M | 26.41M | 9.17M | 13.15M | 13.15M |
| Weighted Avg Shares Out (Dil) | 43.73M | 43.15M | 43.91M | 37.28M | 36.69M | 36.65M | 29.88M | 26.41M | 9.17M | 13.15M | 13.15M |
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
REGENXBIO Announces Leadership Transition
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Source: https://incomestatements.info
Category: Stock Reports